Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
Food and Drug Regulations - Project 1627 - Schedule F Amendment
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The online consultation is now closed. The content found on this page is a snapshot of the live consultation as it was presented to the public and contains the content that was open for submissions during the consultation period.
The purpose of this letter is to provide an opportunity for comment on the proposed addition of three medicinal ingredients - golimumab, lapatinib and its salts, and vorinostat - to Part I of Schedule F to the Food and Drug Regulations.
How to Get Involved
This consultation is open for comment, which would revise the wording of the listings, starting January 11, 2010 until March 27, 2010. Please select and read through the link below titled "consultation document". Once read please submit your comments via email, fax or by mail to:
Refer to Project number 1627
Bureau of Policy, Science and International Programs
"B", Second Floor
Address Locator: 3102C5
Ottawa, Ontario
K1A 0K9
Telephone: (613) 948-4623
Fax: (613) 941-6458
Interested parties are encouraged to provide comments and suggestions by March 27, 2010.
Reporting to Canadians
Health Canada will make the results of this consultation available on this Web site.
If you have any questions, contact us at Regulatory Affairs.
